We zouden het geweldig vinden als je deel wordt van onze community. Word lid van onze Discord om met ons en andere leden in contact te komen!

Ticker
COLO-B.CO

Price
797.20
Stock movement up
+6.80 (0.86%)
Company name
Coloplast A/S
Exchange
(CO
,
Currency
DKK
)
Sector
Healthcare >
Medical Instruments & Supplies
Marktkapitalisatie
165.29B
Ent waarde
194.63B
Prijs/Verkoop
6.12
Prijs/Boek
9.21
Div opbrengst
-
Div groei
-
Jaren van groei
-
FCF-uitkering
320.65%
Trailing P/E
32.72
Toekomstige P/E
29.24
PEG
-
EPS-groei
4.33%
1 jaar rendement
4.26%
3 jaar rendement
-9.92%
5 jaar rendement
0.53%
10 jaar rendement
4.44%
Laatst bijgewerkt: 2024-12-21

DIVIDENDEN

COLO-B.CO keert geen dividend uit

WAARDERING

Waarderingsverhoudingen

Loading...
Gegevens over waarderingsratio's
Trailing P/E32.72
Prijs tot OCF59.76
Prijs tot FCF112.29
Prijs tot EBITDA37.96
EV tot EBITDA44.70

Waardering (verkoop/boekwaarde)

Loading...
Waarderingsgegevens (verkoop/boekwaarde)
Prijs tot verkoop6.12
Prijs te boeken9.21
EV naar verkoop7.20

FINANCIËN

Per aandeel

Loading...
Gegevens per aandeel
Huidig aantal aandelen207.34M
WPA (TTM)22.45
FCF per aandeel (TTM)6.54

Resultatenrekening

Loading...
Gegevens van de resultatenrekening
Inkomsten (TTM)27.03B
Brutowinst (TTM)18.27B
Bedrijfsresultaat (TTM)7.37B
Netto inkomsten (TTM)5.05B
WPA (TTM)22.45
Winst per aandeel (1 jaar vooruit)27.26

Marges

Loading...
Margegegevens
Brutomarge (TTM)67.59%
Operationele marge (TTM)27.25%
Winstmarge (TTM)18.69%

Balans

Loading...
Maak een gratis account aan of log in om toegang te krijgen tot deze grafiek.
Balansgegevens
Cash788.00M
Netto vorderingen4.67B
Totaal vlottende activa10.44B
Goodwill19.38B
Immateriële activa10.96B
Materiële vaste activa13.27B
Totaal activa48.07B
Crediteuren1.52B
Schuld op korte/lange termijn22.63B
Totaal vlottende passiva10.20B
Totaal passiva30.13B
Eigen vermogen17.94B
Netto materiële activa0.00

Kasstroom

Loading...
Maak een gratis account aan of log in om toegang te krijgen tot deze grafiek.
Kasstroomgegevens
Bedrijfskasstroom (TTM)2.77B
Investeringsuitgaven (TTM)1.29B
Vrije kasstroom (TTM)1.47B
Betaalde dividenden (TTM)4.72B

Financieel rendement

Loading...
Maak een gratis account aan of log in om toegang te krijgen tot deze grafiek.
Gegevens over financieel rendement
Rendement op eigen vermogen28.16%
Rendement op activa10.51%
Rendement op geïnvesteerd kapitaal12.60%
Contant rendement op geïnvesteerd kapitaal3.67%

AANDELENINFORMATIE

Voorraadgrafiek

Loading...
Koersgegevens
Open791.60
Dagelijks hoog799.20
Dagelijks laag786.60
Dagelijks volume333K
Hoogtepunt aller tijden1182.50
1y analistenraming926.10
Beta0.34
WPA (TTM)22.45
Dividend per aandeel-
Ex-div datum6 Dec 2024
Volgende inkomsten datum4 Feb 2025

Negatief potentieel

Loading...
Nadeel potentiële gegevens
COLO-B.COS&P500
Huidige prijsdaling vanaf het hoogste punt ooit-32.58%-2.74%
Hoogste prijsdaling-43.67%-56.47%
Datum van hoogste daling28 Oct 19949 Mar 2009
Gemiddelde daling vanaf de top-11.73%-11.13%
Gemiddelde tijd tot nieuwe high16 days12 days
Max tijd tot nieuwe hoogte854 days1805 days
BEDRIJFSGEGEVENS
COLO-B.CO (Coloplast A/S) company logo
Marktkapitalisatie
165.29B
Marktkapitalisatie categorie
Large-cap
Beschrijving
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Werknemers
16639
Investeerdersrelaties
-
CEO
Land
Denmark
Stad
Type aandeel
-
CCC-status
-
Dividendfrequentie
-
EVENEMENTEN EN PRESENTATIES
EvenementenPresentaties
Loading...
HET BEDRIJF BEGRIJPEN
Loading...
BEDRIJFSNIEUWS
Alle nieuwsPersberichten
Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved.Distribution of ye...
5 december 2024
The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. Revenue from the core Skin Care business amounted t...
4 december 2024
On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based produc...
14 november 2024
The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk...
12 november 2024
Coloplast AS (CLPBF) reports robust financial performance with 8% organic growth and strategic product launches, despite facing supply disruptions and competitive pressures.
6 november 2024
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin1. Reported revenue in DKK grew 10% to DKK 27,030 million. Organic growth rates b...
5 november 2024
2023/24 Announcement of full-year financial results 1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraord...
5 november 2024
Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect. “We have entered the final year of...
5 november 2024
Earnings preview of key companies reporting this week and what to look out for.
1 november 2024
Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial...
21 oktober 2024
Volgende pagina